HY Capital
VC Fund
Changning, China
HY Capital is a healthcare industry-focused investment firm that engages in early-stage investments, growth-stage investments.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 52%
Last updated:
For AI agents: llms.txt
Industries HY Capital invests in
Stages HY Capital invests in
Countries HY Capital invests in
Round sizes
Contacts
3 more contacts available
Round size
- Seed
- $83k–$14M
- Series A
- $199k–$16M
- Series B
- $14M–$28M
Investment Focus
Industry
- Health Care 11 (52%)
- Medical 6 (29%)
- Medical Device 5 (24%)
- Biotechnology 4 (19%)
- Manufacturing 3 (14%)
Stage
- Series A 9 (43%)
- Seed 6 (29%)
- Series B 3 (14%)
- Angel 2 (10%)
- Venture - Series Unknown 1 (5%)
Country
- China 19 (90%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Feng Cao
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Yun Liu
Founding Partner & Chairman of the Board
|
Founding Partner & Chairman of the Board | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Only Sanbio
|
Only Sanbio is a synthetic biotechnology company integrating R&D, production, and sales. Itsmed vision is to focus on the field of great health and great beauty, based on synthetic biology technology | $13.7M / Seed / Apr 03, 2025 | |
Linyan Medical
|
Linyan Medical is a high-tech company focusing on the combination of man and machine in metaverse medical surgery. | Venture - Series Unknown / Mar 10, 2025 | |
|
Kang Ruijian
|
Kang Ruijian is a developer of thermosensitive modified chitin hydrogel technology. | Seed / Feb 10, 2025 | |
Onico Medical
|
Onico Medical is a medical device developer. The core team comes from the serious medical field and has absorbed professionals with rich experience in medical aesthetics development. | Seed / Jan 10, 2025 | |
Fibrox
|
Fibrox develops innovative cell therapies based on fibroblasts and clinical requirements for patients. | Seed / Jul 12, 2024 | |
Sylvanus Gene
|
Sylvanus Gene is a gene technology company that focuses on R&D and the production of molecular diagnostic equipment for pathogenic microorganisms. | Angel / Oct 27, 2023 | |
Biotyx Medical
|
Biotyx Medical manufactures and sells iron-based biodegradable vascular materials and stents. | $27.5M / Series B / Sep 01, 2023 | |
Puncture Robotic
|
Puncture Robotic develops venipuncture robots that help in conducting blood collection without human intervention. | $14.2M / Series A / Jul 19, 2023 | |
Chinagene Tech
|
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical geneticdiagnosis services for hereditary ophthalmology patients. | $15.8M / Series A / Mar 30, 2022 | |
Juncell Therapeutics
|
Juncell Therapeutics develops innovative therapies and pharmaceutical drugs for tumor and related treatment. | Series A / Jan 15, 2022 | |
| See all 21 investments → | |||
Co-Investors
ABC Capital
1 deal together
ALAN AMC
1 deal together
Beijing Capital Science and Technology Development Group
1 deal together
Beijing Linkdata Technologies
1 deal together
BioVenture
1 deal together
Crystal Pharmatech
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does HY Capital invest in?
HY Capital invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Seed stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is HY Capital's check size?
HY Capital typically joins rounds of $83k–$14M at Seed, $199k–$16M at Series A and $14M–$28M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HY Capital participates in.
How do I contact HY Capital?
Public channels for HY Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HY Capital?
The team at HY Capital includes Feng Cao (Founding Partner) and Yun Liu (Founding Partner & Chairman of the Board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
